The drug giant sees EPS of 95-98 cents, below analyst views for $1.01. But Merck MRK could report positive results on several drug candidates, said a UBS analyst, who kept a buy rating. The company formed a collaboration with Abbott Laboratories ABT to create a diagnostic test for specific DNA sequences to determine a patient's best course of therapy. Shares fell nearly 3%.
Continue reading at Investor's Business Daily here
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in